risks of glp 1 agonists The cardiovascular effects GLP-1 receptor beyond obesity and type 2 diabetes: An anti-atherosclerotic action Schematic overview of the benefits
Description
Toki S, Newcomb DC, Printz RL, Cahill KN, Boyd KL, Niswender KD, et al
Novo Nordisks Wegovy pill, the first weight-loss drug to win approval from the agency, is expected to launch in the US in early 2026
GLP-1 medications have a substantial clinical evidence base for eligible patients when prescribed and monitored by qualified healthcare professionals
Study Finds GLP-1 Drugs Like Ozempic and Wegovy Not Linked to Pancreatic Cancer Study Finds GLP-1 Drugs Like Ozempic and Wegovy Not Linked to Pancreatic Cancer Recent research findings indicate that drugs belonging to the GLP-1RA class do not pose an increased risk of pancreatic cancer
Cell Discov 10 , 77 (2024)
2011 Jul;34(7):1041-3
